REGN
Regeneron Pharmaceuticals margins
- Stocks
- Healthcare
- NASDAQ: REGN
- Margins
Currently, Regeneron Pharmaceuticals has a gross margin of 85.8%, an operating margin of 28.8%, an EBITDA margin of 37%, and a net margin of 28.5%. Operating margin showed the largest improvement, increasing by 2.9 percentage points. Net margin saw the largest decline, decreasing by 3.6 percentage points.
REGN margin history
Regeneron Pharmaceuticals's margins averaged 85.69% gross, 27.4% operating, 38% EBITDA, and 30.75% net over the last 3 years. Compared with the three-year averages, gross and operating margins are above their three-year averages and EBITDA and net margins are below their three-year averages.
REGN margin expansion
Compared with the same period last year, gross margin expanded by 0.4 percentage points and operating margin by 2.9 percentage points, while EBITDA margin contracted by 3.1 percentage points and net margin by 3.6 percentage points.
REGN Gross margin
Regeneron Pharmaceuticals's gross margin averaged 85.69% over the last 3 years. At present, the current gross margin for Regeneron Pharmaceuticals is 85.8%, 0.1 percentage points above its three-year average. Over the last 3 years, Regeneron Pharmaceuticals's gross margin peaked at 86.3% in Mar 2024 and reached a low of 84.5% in Mar 2026.
REGN Operating margin
Regeneron Pharmaceuticals's operating margin averaged 27.4% over the last 3 years. Compared with its three-year average, Regeneron Pharmaceuticals's current operating margin is 28.8% and is 1.4 percentage points above its three-year average. Over the last 3 years, Regeneron Pharmaceuticals's operating margin peaked at 30.9% in Dec 2023 and reached a low of 24.3% in Mar 2026.
REGN EBITDA margin
Regeneron Pharmaceuticals recorded an average EBITDA margin of 38% across the last 3 years. Regeneron Pharmaceuticals currently reports an EBITDA margin of 37%, 1 percentage point below its three-year average. Over the last 3 years, Regeneron Pharmaceuticals's EBITDA margin peaked at 40.6% in Dec 2025 and reached a low of 34.7% in Mar 2024.
REGN Net margin
Across the last 3 years, Regeneron Pharmaceuticals's net margin averaged 30.75%. The current net margin stands at 28.5%, 2.3 percentage points below its three-year average. Net margin was highest at 33.6% in Sep 2024 and lowest at 27.9% in Jun 2026.
REGN margin group comparison
With a gross margin of 85.8%, REGN is above the Healthcare sector and its peers average but below the industry average. Compared to its Healthcare sector average of 68.4%, Regeneron Pharmaceuticals's gross margin is 25% higher.
REGN margin peer comparison
Frequently asked questions
What is Regeneron Pharmaceuticals's gross margin?
For the period ending Sep 30, 2026, REGN recorded a gross margin of 85.8%.
What is Regeneron Pharmaceuticals's operating margin?
As of Sep 30, 2026, REGN has an operating margin of 28.8%.
What is Regeneron Pharmaceuticals's EBITDA margin?
As of Sep 30, 2026, REGN has an EBITDA margin of 37%.
What is Regeneron Pharmaceuticals's net margin?
As of Sep 30, 2026, REGN has a net margin of 28.5%.
What are the average margins of REGN?
Regeneron Pharmaceuticals's gross, operating, EBITDA, and net margins averaged 85.7% gross, 27.4% operating, 38.0% EBITDA, and 30.8% net over the last 3 years.
What are the highest historical margins of REGN?
In the last 5 years, the highest margins reported by REGN were 87.2% gross in Dec 2022, 55.7% operating in Dec 2021, 60.2% EBITDA in Dec 2021, and 50.2% net in Dec 2021.
What are the lowest historical margins of REGN?
Over the last 5 years, Regeneron Pharmaceuticals's lowest margins were 84.5% gross in Mar 2026, 24.3% operating in Mar 2026, 34.7% EBITDA in Mar 2024, and 27.9% net in Jun 2026.